Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 83

1.

Biceps skin-fold thickness may detect and predict early lipoatrophy in HIV-infected children.

Innes S, Schulte-Kemna E, Cotton MF, Zöllner EW, Haubrich R, Klinker H, Sun X, Jain S, Edson C, van Niekerk M, Innes ER, Rabie H, Browne SH.

Pediatr Infect Dis J. 2013 Jun;32(6):e254-62. doi: 10.1097/INF.0b013e3182814b30.

2.

High prevalence of lipoatrophy in pre-pubertal South African children on antiretroviral therapy: a cross-sectional study.

Innes S, Cotton MF, Haubrich R, Conradie MM, van Niekerk M, Edson C, Rabie H, Jain S, Sun X, Zöllner EW, Hough S, Browne SH.

BMC Pediatr. 2012 Nov 23;12:183. doi: 10.1186/1471-2431-12-183.

3.

Correlates of risk of adipose tissue alterations and their modifications over time in HIV-1-infected women treated with antiretroviral therapy.

Galli M, Ridolfo AL, Adorni F, Cappelletti A, Morelli P, Massetto B, Piazza M, Gianelli E, Vaccarezza M, Gervasoni C, Moroni M.

Antivir Ther. 2003 Aug;8(4):347-54.

PMID:
14518704
4.

Detection of lipoatrophy in human immunodeficiency virus-1-infected children treated with highly active antiretroviral therapy.

Hartman K, Verweel G, de Groot R, Hartwig NG.

Pediatr Infect Dis J. 2006 May;25(5):427-31.

PMID:
16645507
5.

Objective assessment of facial lipoatrophy changes in a cohort of HIV-infected patients taking combination antiretroviral therapy.

Yang Y, Yap M, Oo Tha N, Paton NI.

HIV Clin Trials. 2008 Nov-Dec;9(6):399-406. doi: 10.1310/hct0906-399.

PMID:
19203905
6.

Prevalence of lipodystrophy in HIV-infected children in Tanzania on highly active antiretroviral therapy.

Kinabo GD, Sprengers M, Msuya LJ, Shayo AM, van Asten H, Dolmans WM, van der Ven AJ, Warris A.

Pediatr Infect Dis J. 2013 Jan;32(1):39-44. doi: 10.1097/INF.0b013e3182755a34.

PMID:
23038217
7.

Discordance between body mass index and anthropometric measurements among HIV-1-infected patients on antiretroviral therapy and with lipoatrophy/lipohypertrophy syndrome.

Soares LR, da Silva DC, Gonsalez CR, Batista FG, Fonseca LA, Duarte AJ, Casseb J.

Rev Inst Med Trop Sao Paulo. 2015 Mar-Apr;57(2):105-10. doi: 10.1590/S0036-46652015000200002.

8.

Assessment of ultrasound for use in detecting lipoatrophy in HIV-infected patients taking combination antiretroviral therapy.

Viskovic K, Richman I, Klasnic K, Hernandez A, Krolo I, Rutherford GW, Romih V, Begovac J.

AIDS Patient Care STDS. 2009 Feb;23(2):79-84. doi: 10.1089/apc.2008.0118.

9.

How much fat loss is needed for lipoatrophy to become clinically evident?

Podzamczer D, Ferrer E, Martínez E, Del Rio L, Rosales J, Curto J, Ribera E, Barrufet P, Llibre JM, Aranda M; ABCDE Study Team..

AIDS Res Hum Retroviruses. 2009 Jun;25(6):563-7. doi: 10.1089/aid.2008.0264.

PMID:
19500014
10.

Regional adipose tissue measured by MRI over 5 years in HIV-infected and control participants indicates persistence of HIV-associated lipoatrophy.

Grunfeld C, Saag M, Cofrancesco J Jr, Lewis CE, Kronmal R, Heymsfield S, Tien PC, Bacchetti P, Shlipak M, Scherzer R; Study of Fat Redistribution and Metabolic Change in HIV Infection (FRAM)..

AIDS. 2010 Jul 17;24(11):1717-26. doi: 10.1097/QAD.0b013e32833ac7a2.

11.

Changes in facial fat in HIV-related lipoatrophy, wasting, and weight gain measured by magnetic resonance imaging.

Paton NI, Yang Y, Tha NO, Sitoh YY.

HIV Clin Trials. 2007 Jul-Aug;8(4):227-34.

PMID:
17720663
12.

Incidence of and risk factors for lipoatrophy (abnormal fat loss) in ambulatory HIV-1-infected patients.

Lichtenstein KA, Delaney KM, Armon C, Ward DJ, Moorman AC, Wood KC, Holmberg SD; HIV Outpatient Study Investigators..

J Acquir Immune Defic Syndr. 2003 Jan 1;32(1):48-56.

PMID:
12514413
14.

HIV lipodystrophy: prevalence, severity and correlates of risk in Australia.

Miller J, Carr A, Emery S, Law M, Mallal S, Baker D, Smith D, Kaldor J, Cooper DA.

HIV Med. 2003 Jul;4(3):293-301.

15.

Pronounced lipoatrophy in HIV-infected men receiving HAART for more than 6 years compared with the background population.

Hansen AB, Lindegaard B, Obel N, Andersen O, Nielsen H, Gerstoft J.

HIV Med. 2006 Jan;7(1):38-45.

16.

Reversibility of lipoatrophy in HIV-infected patients 2 years after switching from a thymidine analogue to abacavir: the MITOX Extension Study.

Martin A, Smith DE, Carr A, Ringland C, Amin J, Emery S, Hoy J, Workman C, Doong N, Freund J, Cooper DA; Mitochondrial Toxicity Study Group..

AIDS. 2004 Apr 30;18(7):1029-36.

PMID:
15096806
17.

Single-slice computed tomography and anthropometric skinfold analysis for evaluation of facial lipoatrophy in HIV-infected patients.

Padilla S, Gallego JA, Masiá M, Gutiérrez F.

Clin Infect Dis. 2004 Dec 15;39(12):1848-51. Epub 2004 Nov 21.

PMID:
15578410
18.

Abacavir substitution for nucleoside analogs in patients with HIV lipoatrophy: a randomized trial.

Carr A, Workman C, Smith DE, Hoy J, Hudson J, Doong N, Martin A, Amin J, Freund J, Law M, Cooper DA; Mitochondrial Toxicity (MITOX) Study Group..

JAMA. 2002 Jul 10;288(2):207-15.

PMID:
12095385
19.
20.

A randomized, placebo-controlled trial of rosiglitazone for HIV-related lipoatrophy.

Cavalcanti RB, Raboud J, Shen S, Kain KC, Cheung A, Walmsley S.

J Infect Dis. 2007 Jun 15;195(12):1754-61. Epub 2007 May 2.

PMID:
17492590

Supplemental Content

Support Center